Research‑Grade mRNA That Moves as Fast as Your Ideas

Messenger RNA (mRNA) has become a workhorse of vaccine and therapeutic discovery, but its pace is unforgiving. Project teams now need dozens of constructs, with different sequences, cap analogs, nucleoside mixes, and/or UTR, delivered in weeks, not months. They also need those mRNAs to meet increasingly stringent quality demands.

However, when sourcing research-grade mRNA, it is best to consider the ultimate goal, which is typically the GMP production of the lead construct for clinical studies. Can the mRNA CDMO under consideration serve as a true partner throughout the journey, and what grades of mRNA are required along the way, from screening to clinical product?

As mRNA programs progress from discovery to the clinic, the requirements for quality, documentation, and regulatory alignment evolve. Vernal Biosciences offers three distinct mRNA manufacturing grades: research-grade, GMP-like, and GMP-grade, to support development programs throughout their various phases.

Ideal for early-stage in vitro work, where speed and cost efficiency are key. With rapid turnaround times, essential quality checks, and budget-friendly pricing, this format supports high-throughput screening and fast iteration. Researchers can evaluate multiple constructs or process conditions to identify promising candidates for further development, without the overhead of GMP compliance.

Serves as a bridge between research and clinical manufacturing. Produced with enhanced documentation and process control, it mirrors many GMP principles, such as traceability and batch records; however, GMP quality control and documentation are not required. GMP-like mRNA is well-suited for preclinical studies, pilot toxicology work, and process optimization, allowing teams to refine protocols and de-risk scale-up without the cost of full GMP production.

Meets the most rigorous quality and regulatory standards required for clinical trials and commercialization. mRNA is manufactured under validated, GMP conditions, with extensive quality control and full traceability. GMP-grade material is essential for Investigational New Drug (IND) submissions, where chemistry, manufacturing, and controls (CMC) documentation must demonstrate a robust and reproducible process. Engineering runs and process performance qualification (PPQ) are key milestones supported by GMP production, ensuring the safety, consistency, and scalability required for human use.

While it is highly recommended to select an mRNA partner that can support your program from discovery through the clinical and commercialization phases, research-grade product is the starting point. What is needed from a research-grade mRNA product to support lead screening, lead down-selection, and mRNA for early-phase process development work?

Scientists need microgram-scale quantities quickly so they can iterate rapid design-build-test cycles.

96- or 24-well plates are formatted specifically for automated liquid handling systems, eliminating the need for tube re-arraying.

Full-length purity, capping efficiency, and dsRNA burden need to be quantified, because even picogram levels of contaminant can skew readouts.

mRNA candidates may require modified nucleoside triphosphates (NTPs), 5′ cap options, and/or RNA polymerase options, and include various sequence lengths.

Ultimately, researchers require an mRNA partner that can rapidly produce high-quality, research-grade mRNA and then be prepared to collaborate on scaling, formulating, and preparing the therapeutic for clinical use.

Vernal Biosciences designed its research-grade mRNA manufacturing service to meet the needs of discovery-phase research, while keeping the clinic in mind. In the 96‑well plate format, researchers receive up to 96 capped and polyadenylated mRNAs, including controls, purified in parallel, ensuring consistency. Typical yields (50–100 µg per well) are ideal for rapid lead screening. Designed for lead down selection, the 24-well format provides milligram-scale quantities (1–5 mg) within the same automation-friendly footprint. Higher volumes of product (2mg to 500mg) are supplied in conical tubes for lead optimization or other early-phase work.

Because Vernal manufactures GMP‑grade plasmid DNA, mRNA drug substance, and mRNA-LNP drug product on the same campus, clients avoid costly and time-consuming tech transfers. A sequence screened in a 96-well plate can flow directly into manufacturing for lead optimization at a 500 mg scale, then into LNP formulation and IND-enabling studies, guided by the same project manager and quality control playbook. That continuum cuts months off the typical discovery-to-clinic timeline and removes the supply-chain bottlenecks many programs face when transitioning from academic or other discovery-phase labs to a CDMO.

Teams that adopt plate-based mRNA approaches in their proof-of-concept and discovery phases typically considerably shorten the design-build-test cycles from months to weeks, freeing time and bandwidth to explore additional hypotheses as needed. Research programs utilizing plate-based libraries also consume fewer cells, reagents, and animals because hit ranking occurs early and on plate, before expensive in vivo research is conducted. That efficiency translates into tangible milestones: faster validation and robust data packages supporting successful regulatory filings.

Whether you’re scanning 96 mRNA variants or optimizing a smaller number of lead constructs with first‑in‑human studies in mind, Vernal Biosciences delivers the speed, quality, and seamless scale‑up today’s mRNA innovators demand. We’ll turn your next idea into clinic‑ready reality, one plate at a time. Contact us to learn more.